Incyte Corp
A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
Holds 89.3x more cash than debt — a strong balance sheet.
Current Price
$96.91
+1.72%GoodMoat Value
$271.40
180.1% undervaluedIncyte Corp (INCY) Insider Trades
INCY Insider Trading Activity
Track insider trading transactions for Incyte Corp (INCY). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $96.91. Market cap: $19.29B. This page displays the most recent insider transactions for INCY, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Incyte Corp's investment outlook.